The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network

Greg Hapgood, Monica Civallero, Yana Stepanishyna, Julie M Vose, Maria Elena Cabrera, Ranjana H Advani, Stefano A Pileri, Martina Manni, Steven M Horwitz, Francine M Foss, Felicitas Hitz, John Radford, Ivan Dlouhy, Carlos Sérgio Chiattone, Won-Seog Kim, Tetiana Skrypets, Arnon Nagler, Judith Trotman, Stefano Luminari, Massimo Federico

Research output: Contribution to journalArticlepeer-review


The natural history of limited-stage peripheral T-cell lymphomas (PTCLs) remains poorly defined. We investigated outcomes and prognostic variables in patients registered in the T-Cell Project (TCP)(NCT01142674) to develop a model to predict overall survival (OS) for the common nodal PTCL subtypes (PTCL-NOS, AITL, ALCL). The model was validated in an independent data set from Australian and Brazilian registries. 211 patients registered in the TCP between 2006-2018 were studied. The median age was 59 years (range 18-88) and median follow-up was 49 months. 127 patients (78%) received anthracycline-based regimens, 5 patients (3%) radiotherapy alone (RT), 24 patients (15%) chemotherapy+RT. 5-year OS and PFS were 47% and 37%, respectively. Age >60y, elevated LDH and low serum albumin were independent prognostic factors. The model identified three groups with low- (26%, score 0), intermediate- (41%, score 1), and high-risk (33%, score 2-3) with 5-yr OS of 78% [95% CI 29-127], 46% [95% CI 24-68], and 25% [95% CI 20-30], respectively (P<0·001) and 5-yr PFS of 66% [95% CI 33-99], 37% [95% CI 9-65], and 17% [95% CI 9-25], respectively (P<0·001). The model demonstrated greater discriminatory power than established prognostic indices and an analogous distribution and outcomes in the three groups in the validation cohort of 103 patients. The SALENTO Model (Limited Stage Peripheral T Cell Lymphoma Prognostic Model) is an objective, simple and robust prognostic tool. The high-risk group has poor outcomes, comparable to advanced stage disease, and should be considered for innovative first-line approaches.

Original languageEnglish
JournalBlood Advances
Early online date10 May 2023
Publication statusE-pub ahead of print - 10 May 2023


Dive into the research topics of 'The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network'. Together they form a unique fingerprint.

Cite this